UY29178A1 - Inhibidores de quinasa c-fms - Google Patents

Inhibidores de quinasa c-fms

Info

Publication number
UY29178A1
UY29178A1 UY29178A UY29178A UY29178A1 UY 29178 A1 UY29178 A1 UY 29178A1 UY 29178 A UY29178 A UY 29178A UY 29178 A UY29178 A UY 29178A UY 29178 A1 UY29178 A1 UY 29178A1
Authority
UY
Uruguay
Prior art keywords
treatment
diseases
compounds
formula
well
Prior art date
Application number
UY29178A
Other languages
English (en)
Inventor
Carl R Illig
Shelley K Ballentine
Jinsheng Chen
Sanath Meegalla
M Jonathan Rudoplh
Mark J Wall
Renee Desjarlais
Ken Wilson
Christopher J Molloy
Carl L Manthey
Christopher Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY29178A1 publication Critical patent/UY29178A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/70—Nitro radicals
    • C07D307/71—Nitro radicals attached in position 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de la fórmula I en ella A, X, R2 y W se definen en memoria descriptiva, así como solvatos, hidratos, tautómeros y sales farmacéuticamente aceptables de los mismos, que inhiben las tirosin quinasas de proteína, especialmente la quinasa c-fms. También se proporcionan métodos para el tratamiento de enfermedades autoinmunes, y enfermedades con un componente inflamatorio; tratamiento de matástasis de cáncer ovárico, de útero, de mama, de colon, de estómago, leucemia de célula pilosa y carcinoma de pulmón de célula no pequena, y tratamiento de dolor, incluyendo dolor esquelético causado por metástasis tumoral u osteoartritis, o dolor visceral, inflamatorio, y neurogénico, así como también osteoporosis, enfermedad de Paget y otras enfermedades en las cuales la resorción ósea media la morbilidad incluyendo artritis, paro de prostesis, sarcoma osteolítico, mieloma, y metástasis tumoral al hueso, con los compuestos de la fórmula I.
UY29178A 2004-10-22 2005-10-24 Inhibidores de quinasa c-fms UY29178A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62121104P 2004-10-22 2004-10-22
US67017205P 2005-04-11 2005-04-11
US11/254,276 US7662837B2 (en) 2004-10-22 2005-10-20 Inhibitors of c-fms kinase

Publications (1)

Publication Number Publication Date
UY29178A1 true UY29178A1 (es) 2006-03-31

Family

ID=40433511

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29178A UY29178A1 (es) 2004-10-22 2005-10-24 Inhibidores de quinasa c-fms

Country Status (10)

Country Link
US (1) US7662837B2 (es)
AR (1) AR051599A1 (es)
EC (1) ECSP077409A (es)
IL (1) IL182735A (es)
MY (1) MY145668A (es)
NZ (1) NZ555289A (es)
PE (1) PE20060724A1 (es)
SV (1) SV2006002669A (es)
TW (1) TWI377942B (es)
UY (1) UY29178A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
BRPI0710548B8 (pt) * 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
EP2021329B1 (en) * 2006-04-20 2016-04-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
ATE510832T1 (de) 2006-04-20 2011-06-15 Janssen Pharmaceutica Nv Heterocyclische verbindungen als c-fms- kinasehemmer
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2013299922B2 (en) 2012-08-07 2018-06-21 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190541A (en) * 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5702390A (en) * 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
WO2000042042A2 (en) * 1999-01-11 2000-07-20 Princeton University High affinity inhibitors for target validation and uses thereof
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
AU779089B2 (en) * 1999-04-15 2005-01-06 Bristol-Myers Squibb Holdings Ireland Unlimited Company Cyclic protein tyrosine kinase inhibitors
US6346625B1 (en) * 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) * 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6613809B2 (en) * 2001-11-28 2003-09-02 The Regents Of The University Of California Metal-doped organic gels and method thereof
BRPI0409136A (pt) * 2003-04-09 2006-04-25 Japan Tobacco Inc composto heteroaromático pentacìclico e uso medicinal do mesmo
JP2007525460A (ja) * 2003-04-25 2007-09-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ｃ−ｆｍｓキナーゼ阻害剤
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
IL182735A0 (en) 2007-09-20
AR051599A1 (es) 2007-01-24
US7662837B2 (en) 2010-02-16
MY145668A (en) 2012-03-15
IL182735A (en) 2013-10-31
TWI377942B (en) 2012-12-01
ECSP077409A (es) 2007-05-30
TW200630092A (en) 2006-09-01
SV2006002669A (es) 2009-10-15
US20060148812A1 (en) 2006-07-06
PE20060724A1 (es) 2006-09-01
NZ555289A (en) 2010-10-29

Similar Documents

Publication Publication Date Title
UY31397A1 (es) Inhibidores de quinasa c-fms
UY29178A1 (es) Inhibidores de quinasa c-fms
UA88648C2 (en) Inhibitors of c-fms kinase
ATE437864T1 (de) Aromatische amide als hemmer der c-fms-kinase
UA93085C2 (en) Inhibitors of c-fms kinase
PT2021335E (pt) Compostos heterocíclicos como inibidores de c-fms quinase
FIC20210022I1 (fi) tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
CY1118112T1 (el) Διυποκατεστημενες βενζοθειενυλ-πυρρολοτριαζινες και η χρηση τους ως αναστολεις κινασης υποδοχεα του αυξητικου παραγοντα των ινοβλαστων (fgfr)
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
CL2008001230A1 (es) Compuestos derivados de pirrol (2.3-d)pirimidina. purin-6-ilo o pirazol(3,4-d)pirimldina, inhibidores de quinasa p70 s6; composición farmaceutica; y uso para la preparación de medicamentos utiles en el tratamiento de adenocarcinomas del colon e inhibición de angiogénesis.
CY1112142T1 (el) Κυκλοπεντα [d] πυριμιδινες ως αναστολεις της κινασης πρωτεϊνης του ακτ
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
EA201400575A1 (ru) Способы получения ингибиторов jak киназ и родственных промежуточных соединений
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
ES2667847T3 (es) Pirimidinas sustituidas útiles como inhibidores de cinasa de EGFR-T790M
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
ECSP034776A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
AR026037A1 (es) Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos
UY26988A1 (es) Nuevas indolinonas sustituidas, su preparación y su utilización como medicamentos.
TW200745090A (en) Chemical compounds
HK1122795A1 (en) Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
UY27241A1 (es) Indolinonas sustituidas en posiciones 6, su preparación y utilización como medicamentos
UY27968A1 (es) Derivados de indolinona sustituidos con heterociclos, su preparación y su utilización como medicamentos.
TH90382B (th) อนุพันธ์แอซะอินโดล-2-คาร์บอกซาไมด์
UY26389A1 (es) Indolinonas sustituidas en posición 6, su preparación y su utilización como medicamentos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200624